Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD

As a treatment for asthma, Dupixent helps patients breathe. Appropriately enough, Sanofi and Regeneron are breathing easy after Dupixent posted impressive data in a high-risk trial assessing its effectiveness against chronic obstructive pulmonary disease (COPD).